ArticleF1000 biology reports2011
Drugs for malaria: something old, something new, something borrowed.
Article in F1000 biology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Ontological representation, modeling, and analysis of parasite vaccines.Journal of biomedical semantics · 2024Article
- Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.Journal of medicinal chemistry · 2022Article
- Evaluation of the Antimalarial Activity of Ethanol Extracts of the Leaves of Three Plant Species Collected from Yayu Coffee Forest Biosphere Reserve, Southwest Ethiopia.Journal of experimental pharmacology · 2021Article
- Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges.BioMed research international · 2021Review
- The Ototoxicity of Antimalarial Drugs-A State of the Art Review.Frontiers in neurology · 2021Review
- Structural and Biochemical Characterization of Apicomplexan Inorganic Pyrophosphatases.Scientific reports · 2017Article
- Triple Combination Therapy and Drug Cycling-Tangential Strategies for Countering Artemisinin Resistance.Current infectious disease reports · 2017Review
- The need to compare: assessing the level of agreement of three high-throughput assays against Plasmodium falciparum mature gametocytes.Scientific reports · 2017Article
- Development in Assay Methods forFrontiers in pharmacology · 2017Review
- Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.Drug design, development and therapy · 2016Review
- Antimalarial activity of cupredoxins: the interaction of Plasmodium merozoite surface protein 119 (MSP119) and rusticyanin.The Journal of biological chemistry · 2013Article
- An image analysis algorithm for malaria parasite stage classification and viability quantification.PloS one · 2013Article
- Malaria parasite-synthesized heme is essential in the mosquito and liver stages and complements host heme in the blood stages of infection.PLoS pathogens · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Malaria was estimated to cause 800,000 deaths and 225 million cases worldwide in 2010. Worryingly, the first-line treatment currently relies on a single drug class called artemisinins, and there are signs that the parasite is becoming resistant to these drugs. The good news is that new technology has given us new approaches to drug discovery. New drugs generated this way are probably 10-15 years away from the clinic. Other antimalarials that may offer hope include those rehabilitated after not being used for some time, those that act as inhibitors of resistance mechanisms, those that limit infection while allowing protective immunity to develop, and those which are drugs borrowed from other disease treatments. All of these offer new hope of turning the tables on malaria. In parallel with the effort to develop vaccines that interrupt malaria transmission, drugs that target the parasite during transmission to the mosquito or during its pre-erythrocytic development in the liver, may allow us to terminate the parasite's spread.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.